Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Go back to Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform| (NASDAQ: PSNL) | Delayed: 12.47 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.47 | 52 Week High | $ | |||
| Open | $12.47 | 52 Week Low | $ | |||
| Day High | $12.47 | P/E | N/A | |||
| Day Low | $12.47 | EPS | $ | |||
| Volume | 9,903 | |||||
| StemCells, Inc. (NASDAQ: TEM) | Delayed: 46.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.96 | 52 Week High | $0.45 | |||
| Open | $46.96 | 52 Week Low | $0.37 | |||
| Day High | $46.96 | P/E | N/A | |||
| Day Low | $46.96 | EPS | $-0.31 | |||
| Volume | 111,809 | |||||

